Literature DB >> 35378023

Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY.

Nattawat Klomjit1, Ladan Zand1.   

Abstract

Entities:  

Keywords:  MN; Ponticelli regimen; cyclophosphamide; glomerular and tubulointerstitial diseases; glomerulonephritis; membranous; membranous nephropathy; rituximab

Mesh：

Substances：

Year:  2021        PMID： 35378023      PMCID： PMC8785832          DOI： 10.34067/KID.0002492021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  18 in total

1.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Authors:  Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

2.  Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.

Authors:  K Dahan; C Johannet; E Esteve; E Plaisier; H Debiec; P Ronco
Journal:  Kidney Int       Date:  2019-01       Impact factor: 10.612

3.  The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.

Authors:  Gema Fernández-Juárez; Jorge Rojas-Rivera; Anne-Els van de Logt; Joana Justino; Angel Sevillano; Fernando Caravaca-Fontán; Ana Ávila; Cristina Rabasco; Virginia Cabello; Alfonso Varela; Montserrat Díez; Guillermo Martín-Reyes; Marian Goicoechea Diezhandino; Luis F Quintana; Irene Agraz; Juan Ramón Gómez-Martino; Mercedes Cao; Antolina Rodríguez-Moreno; Begoña Rivas; Cristina Galeano; Jose Bonet; Ana Romera; Amir Shabaka; Emmanuelle Plaisier; Mario Espinosa; Jesus Egido; Alfonso Segarra; Gérard Lambeau; Pierre Ronco; Jack Wetzels; Manuel Praga
Journal:  Kidney Int       Date:  2020-11-07       Impact factor: 10.612

4.  Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

Authors:  Jan A J G van den Brand; Piero Ruggenenti; Antonietta Chianca; Julia M Hofstra; Annalisa Perna; Barbara Ruggiero; Jack F M Wetzels; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-05-09       Impact factor: 10.121

Review 5.  A Proposal for a Serology-Based Approach to Membranous Nephropathy.

Authors:  An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 10.121

6.  Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases.

Authors:  Nattawat Klomjit; Fernando C Fervenza; Ladan Zand
Journal:  Am J Kidney Dis       Date:  2020-04-18       Impact factor: 8.860

Review 7.  Primary Membranous Nephropathy.

Authors:  William G Couser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

8.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.

Authors:  Vivekanand Jha; Anirban Ganguli; Tarun K Saha; Harbir S Kohli; Kamal Sud; Krishan L Gupta; Kusum Joshi; Vinay Sakhuja
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

9.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Authors:  Francesco Scolari; Elisa Delbarba; Domenico Santoro; Loreto Gesualdo; Antonello Pani; Nadia Dallera; Laila-Yasmin Mani; Marisa Santostefano; Sandro Feriozzi; Marco Quaglia; Giuliano Boscutti; Angelo Ferrantelli; Carmelita Marcantoni; Patrizia Passerini; Riccardo Magistroni; Federico Alberici; Gian Marco Ghiggeri; Claudio Ponticelli; Pietro Ravani
Journal:  J Am Soc Nephrol       Date:  2021-03-01       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.